In our series of interviews with leading innovation and venture developers, Andrew Gaule, left, founder of the Corporate Venturing Network, talks to David Phillips, partner at SR One, GlaxoSmithKline's corporate venturing unit.
Gaule: Give a brief description of the SR One fund and why it was developed to meet the needs of GlaxoSmithKline (GSK).
Phillips: SR One has been around since 1985 to pro-vide strategic insights for GSK and deliver a financial return. It is seen as a scientifc crow’s nest, looking at technologies four to fve years out which will be important for GSK. There is a strong drive in the pharmaceutical industry to externalise research and development (R&D) and GSK…
